Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Phase II trial of curcumin in patients with advanced pancreatic cancer.

Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R.

Clin Cancer Res. 2008 Jul 15;14(14):4491-9. doi: 10.1158/1078-0432.CCR-08-0024.

2.
3.

Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products.

Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal BB, Krishnan S.

Clin Cancer Res. 2008 Apr 1;14(7):2128-36. doi: 10.1158/1078-0432.CCR-07-4722.

4.

Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells.

Sharma C, Kaur J, Shishodia S, Aggarwal BB, Ralhan R.

Toxicology. 2006 Nov 10;228(1):1-15. Epub 2006 Aug 12.

PMID:
16996673
5.
6.

The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia.

Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP.

Biol Psychiatry. 2009 Mar 15;65(6):481-8. doi: 10.1016/j.biopsych.2008.10.018. Epub 2008 Dec 5.

PMID:
19058794
7.

Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase.

Cohen AN, Veena MS, Srivatsan ES, Wang MB.

Arch Otolaryngol Head Neck Surg. 2009 Feb;135(2):190-7. doi: 10.1001/archotol.135.2.190.

PMID:
19221248
8.

"Spicing up" of the immune system by curcumin.

Jagetia GC, Aggarwal BB.

J Clin Immunol. 2007 Jan;27(1):19-35. Epub 2007 Jan 9. Review.

PMID:
17211725
9.

Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors.

Kamat AM, Tharakan ST, Sung B, Aggarwal BB.

Cancer Res. 2009 Dec 1;69(23):8958-66. doi: 10.1158/0008-5472.CAN-09-2045. Epub 2009 Nov 10.

10.
12.

Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.

Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP.

Clin Cancer Res. 2001 Jul;7(7):1894-900.

13.

Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance.

Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP.

Clin Cancer Res. 2004 Oct 15;10(20):6847-54.

14.

A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.

Gharibo M, Patrick-Miller L, Zheng L, Guensch L, Juvidian P, Poplin E.

Pancreas. 2008 May;36(4):341-5. doi: 10.1097/MPA.0b013e31815d50f9.

PMID:
18437079
15.

Fructus Xanthii extract protects against cytokine-induced damage in pancreatic beta-cells through suppression of NF-kappaB activation.

Song MY, Kim EK, Lee HJ, Park JW, Ryu DG, Kwon KB, Park BH.

Int J Mol Med. 2009 Apr;23(4):547-53.

PMID:
19288032
16.
17.

A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.

Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1521-30. doi: 10.1007/s00280-013-2151-8. Epub 2013 Mar 30.

PMID:
23543271
18.

Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.

Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, Duarte VM, Faull KF, Mehta K, Srivatsan ES, Wang MB.

Clin Cancer Res. 2008 Oct 1;14(19):6228-36. doi: 10.1158/1078-0432.CCR-07-5177.

19.

Effects of curcumin in an orthotopic murine bladder tumor model.

Leite KR, Chade DC, Sanudo A, Sakiyama BY, Batocchio G, Srougi M.

Int Braz J Urol. 2009 Sep-Oct;35(5):599-606; discussion 606-7.

20.

Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy.

Logan RM, Gibson RJ, Sonis ST, Keefe DM.

Oral Oncol. 2007 Apr;43(4):395-401. Epub 2006 Sep 18.

PMID:
16979925

Supplemental Content

Support Center